Due to the potential of BIONIME’s excellent technology, development team and the market for blood sugar monitoring, the GSIF decided to invest in BIONIME on September 5 2005 . Apart from the financial investment, the GSIF’s immense network of industrial contacts is also available to assist in the future growth of BIONIME.